Tandem Diabetes Care - TNDM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $75.50
  • Forecasted Upside: 71.86%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$43.93
▲ +0.66 (1.53%)

This chart shows the closing price for TNDM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

Analyst Price Target is $75.50
▲ +71.86% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $75.50, with a high forecast of $130.00 and a low forecast of $43.00. The average price target represents a 71.86% upside from the last price of $43.93.

This chart shows the closing price for TNDM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2023Wolfe ResearchInitiated CoveragePeer PerformN/A
12/12/2022CitigroupBoost Target$50.00 ➝ $55.00Low
11/15/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$43.00Low
11/4/2022Raymond JamesLower TargetOutperform$92.00 ➝ $52.00Low
11/3/2022CowenLower Target$107.00 ➝ $61.00Low
11/3/2022Lake Street CapitalLower Target$150.00 ➝ $60.00Low
11/3/2022Craig HallumLower Target$105.00 ➝ $80.00Low
11/3/2022CowenLower Target$107.00 ➝ $61.00Low
11/3/2022Robert W. BairdLower Target$76.00 ➝ $45.00Low
11/3/2022Piper SandlerLower TargetOverweight$80.00 ➝ $70.00Low
10/17/2022BarclaysInitiated CoverageOverweight$75.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$75.00Low
10/5/2022CitigroupLower Target$98.00 ➝ $75.00Low
8/9/2022Robert W. BairdLower Target$76.00Low
8/9/2022Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$82.00 ➝ $49.00Low
8/4/2022Lake Street CapitalLower Target$200.00 ➝ $150.00Low
8/4/2022CowenLower Target$141.00 ➝ $107.00Low
8/4/2022Piper SandlerLower TargetOverweight$120.00 ➝ $80.00N/A
8/4/2022Wells Fargo & CompanyLower TargetOverweight$166.00 ➝ $82.00Low
8/4/2022Raymond JamesLower TargetOutperform$125.00 ➝ $90.00Low
8/4/2022CowenLower Target$141.00 ➝ $107.00Low
8/4/2022CitigroupLower Target$107.00 ➝ $98.00Low
5/17/2022CitigroupLower Target$155.00 ➝ $130.00Medium
5/5/2022OppenheimerLower Target$142.00 ➝ $130.00High
5/5/2022Piper SandlerLower Target$170.00 ➝ $120.00High
4/18/2022SVB LeerinkReiterated RatingMarket PerformHigh
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral$130.00Low
2/23/2022Wells Fargo & CompanyBoost TargetOverweight$160.00 ➝ $166.00High
2/23/2022CitigroupLower TargetBuy$163.00 ➝ $155.00High
2/23/2022SVB LeerinkLower TargetMarket Perform$140.00 ➝ $120.00High
1/19/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$137.00 ➝ $160.00High
12/7/2021Lake Street CapitalBoost TargetBuy$165.00 ➝ $200.00High
12/6/2021Piper SandlerBoost TargetOverweight$140.00 ➝ $150.00High
11/4/2021Wells Fargo & CompanyBoost TargetEqual Weight$121.00 ➝ $137.00High
11/4/2021SVB LeerinkBoost TargetMarket Perform$135.00 ➝ $140.00High
11/4/2021Raymond JamesBoost TargetOutperform$120.00 ➝ $138.00High
11/4/2021Piper SandlerBoost TargetOverweight$132.00 ➝ $140.00High
9/24/2021SVB LeerinkBoost TargetMarket Perform$123.00 ➝ $135.00Low
8/5/2021SVB LeerinkBoost TargetMarket Perform ➝ Market Perform$102.00 ➝ $123.00Low
8/5/2021OppenheimerBoost TargetOutperform$135.00 ➝ $140.00Low
8/5/2021Craig HallumBoost TargetBuy$140.00 ➝ $153.00High
8/5/2021Wells Fargo & CompanyBoost TargetEqual Weight$112.00 ➝ $121.00High
8/5/2021Raymond JamesBoost TargetOutperform$115.00 ➝ $120.00Medium
5/24/2021BarclaysInitiated CoverageUnderweight$90.00Low
5/6/2021OppenheimerBoost Target$130.00 ➝ $135.00Low
5/6/2021SVB LeerinkBoost TargetMarket Perform$95.00 ➝ $102.00High
4/1/2021SVB LeerinkLower TargetMarket Perform$115.00 ➝ $95.00Low
3/31/2021OppenheimerReiterated RatingBuyHigh
2/25/2021Lake Street CapitalBoost TargetBuy$137.00 ➝ $150.00High
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$105.00High
11/6/2020Raymond JamesBoost TargetOutperform$116.00 ➝ $124.00High
11/6/2020SVB LeerinkBoost TargetMarket Perform$120.00 ➝ $130.00High
11/6/2020Piper SandlerBoost TargetOverweight$125.00 ➝ $132.00High
9/21/2020OppenheimerReiterated RatingBuy$120.00High
8/28/2020SVB LeerinkBoost TargetMarket Perform$115.00 ➝ $120.00Low
8/20/2020Wells Fargo & CompanyInitiated CoverageOverweight$120.00High
7/31/2020Raymond JamesBoost TargetOutperform$95.00 ➝ $116.00Low
7/31/2020Craig HallumBoost TargetBuy$102.00 ➝ $140.00High
7/31/2020Lake Street CapitalBoost TargetPositive ➝ Buy$125.00 ➝ $137.00High
7/31/2020SVB LeerinkBoost TargetMarket Perform$105.00 ➝ $115.00High
7/31/2020GuggenheimUpgradeNeutral ➝ Buy$130.00High
7/31/2020Piper SandlerBoost TargetOverweight$90.00 ➝ $125.00High
7/7/2020CowenBoost TargetPositive ➝ Outperform$85.00 ➝ $110.00Low
7/6/2020CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $120.00Low
6/30/2020OppenheimerInitiated CoverageBuy$102.00Low
6/30/2020Piper SandlerReiterated RatingBuy$90.00Low
6/30/2020Bank of AmericaReiterated RatingHold$100.00Low
6/30/2020CowenReiterated RatingBuy$85.00Low
6/22/2020UBS GroupBoost TargetBuy$98.00 ➝ $106.00Low
6/22/2020OppenheimerBoost TargetReduce ➝ Outperform$92.00 ➝ $102.00Low
6/18/2020Lake Street CapitalBoost Target$100.00 ➝ $125.00Low
6/18/2020Raymond JamesBoost TargetOutperform$88.00 ➝ $95.00Low
6/17/2020OppenheimerInitiated CoverageBuy$92.00Low
6/3/2020CitigroupBoost TargetAverage ➝ Neutral$81.00 ➝ $94.00Low
5/22/2020Bank of AmericaBoost TargetNeutral$85.00 ➝ $95.00Low
5/1/2020UBS GroupLower TargetBuy$100.00 ➝ $98.00High
5/1/2020CitigroupBoost TargetNeutral$74.00 ➝ $81.00High
5/1/2020Stifel NicolausBoost TargetHold$65.00 ➝ $75.00Medium
5/1/2020OppenheimerReiterated RatingBuy$92.00High
5/1/2020SVB LeerinkBoost TargetMarket Perform$85.00 ➝ $88.00High
4/27/2020Raymond JamesLower TargetOutperform$91.00 ➝ $81.00Low
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/20/2020Craig HallumLower TargetBuy$108.00 ➝ $102.00Medium
3/27/2020CitigroupLower TargetNeutral$89.00 ➝ $74.00High
3/23/2020GuggenheimDowngradeBuy ➝ NeutralHigh
3/4/2020CitigroupInitiated CoverageNeutral$89.00Medium
2/25/2020OppenheimerBoost Target$84.00 ➝ $97.00High
2/25/2020Piper SandlerBoost TargetOverweight$70.00 ➝ $90.00High
2/25/2020Craig HallumBoost TargetBuy$92.00 ➝ $108.00High
2/25/2020Stifel NicolausBoost TargetHold$70.00 ➝ $77.00High
2/25/2020Raymond JamesBoost TargetOutperform$85.00 ➝ $91.00High
2/25/2020CowenReiterated RatingOutperform$85.00 ➝ $90.00High
2/13/2020CowenBoost TargetOutperform$70.00 ➝ $85.00Medium
2/12/2020Craig HallumReiterated RatingBuy$92.00High
2/5/2020Raymond JamesInitiated CoverageOutperform$85.00Low
2/4/2020Robert W. BairdDowngradeOutperform ➝ Neutral$71.00 ➝ $75.00Low
12/13/2019Craig HallumReiterated RatingBuy$92.00Low
10/17/2019GuggenheimInitiated CoverageBuy$76.00Low
10/4/2019UBS GroupUpgradeNeutral ➝ Buy$75.00Low
8/2/2019OppenheimerBoost Target$80.00 ➝ $84.00Medium
6/17/2019Lake Street CapitalReiterated RatingBuyMedium
5/17/2019Bank of AmericaReiterated RatingNeutral$65.00Medium
5/13/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$83.00Low
5/1/2019OppenheimerBoost TargetOutperform$68.00 ➝ $80.00Medium
5/1/2019Stifel NicolausBoost TargetHold ➝ Hold$58.00 ➝ $70.00Medium
5/1/2019Craig HallumReiterated RatingBuy$70.00 ➝ $84.00High
4/30/2019UBS GroupBoost TargetNeutral ➝ Neutral$53.00 ➝ $66.00High
3/8/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$77.00High
3/5/2019Bank of AmericaBoost TargetNeutral$59.00 ➝ $65.00Low
2/27/2019OppenheimerBoost TargetOutperform$57.00 ➝ $68.00Medium
2/27/2019CowenBoost TargetOutperform$40.00 ➝ $60.00Medium
2/27/2019Craig HallumBoost TargetBuy$59.00 ➝ $70.00Medium
2/27/2019Lake Street CapitalBoost TargetBuy ➝ Buy$60.00 ➝ $100.00High
2/27/2019Piper Jaffray CompaniesUpgradeOverweight$67.00High
2/15/2019Robert W. BairdBoost TargetOutperform$46.00 ➝ $55.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral$36.00High
11/21/2018Robert W. BairdUpgradeNeutral ➝ Outperform$46.00High
11/9/2018OppenheimerSet TargetBuy$57.00Medium
11/3/2018Lake Street CapitalSet TargetBuy$60.00High
11/2/2018Craig HallumSet TargetBuy$59.00High
11/2/2018OppenheimerSet TargetBuy$57.00High
10/15/2018Lake Street CapitalSet TargetBuy$60.00High
9/26/2018Dougherty & CoBoost TargetBuy$45.00 ➝ $56.00Low
9/26/2018Piper Jaffray CompaniesReiterated RatingAbove Average ➝ Overweight$32.00 ➝ $56.00Medium
9/25/2018OppenheimerReiterated RatingBuy$57.00Low
9/20/2018Craig HallumInitiated CoverageBuy$52.00 ➝ $52.00Low
9/14/2018Robert W. BairdDowngradeOutperform ➝ NeutralMedium
9/5/2018OppenheimerSet TargetBuy$54.00High
8/30/2018Berenberg BankInitiated CoverageBuy ➝ Buy$50.00High
8/24/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$45.00High
8/24/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$45.00High
8/22/2018Stifel NicolausInitiated CoverageHold$25.00 ➝ $34.00High
8/20/2018Lake Street CapitalBoost TargetBuy$35.00 ➝ $65.00Low
8/6/2018OppenheimerSet TargetBuy$31.00 ➝ $38.00High
7/31/2018OppenheimerSet TargetBuy$31.00High
7/31/2018Lake Street CapitalBoost TargetBuy$35.00High
7/31/2018Piper Jaffray CompaniesBoost TargetOverweight$32.00High
7/31/2018Stifel NicolausReiterated RatingHold ➝ Hold$7.50 ➝ $25.00High
7/31/2018CowenReiterated RatingBuy$28.00High
7/23/2018Robert W. BairdReiterated RatingBuy$31.00High
6/22/2018Piper Jaffray CompaniesUpgradeOverweight$25.00High
6/18/2018Lake Street CapitalInitiated CoverageBuy$30.00High
5/27/2018OppenheimerSet TargetBuy$15.00High
5/21/2018OppenheimerSet TargetBuy$10.00 ➝ $15.00High
5/14/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
4/6/2018OppenheimerSet TargetBuy$8.00High
3/28/2018CowenUpgradeMarket Perform ➝ OutperformMedium
3/23/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
3/22/2018OppenheimerReiterated RatingBuyMedium
3/2/2018Stifel NicolausReiterated RatingHold$4.00High
2/27/2018CowenReiterated RatingHoldMedium
2/27/2018CitigroupInitiated CoverageOutperform$5.50Low
2/26/2018OppenheimerInitiated CoverageBuy$5.50 ➝ $6.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.46 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/12/2022
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/11/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/10/2022
  • 13 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 10 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 15 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 15 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Tandem Diabetes Care logo
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $43.93
Low: $42.65
High: $44.15

50 Day Range

MA: $42.41
Low: $39.36
High: $46.50

52 Week Range

Now: $43.93
Low: $33.51
High: $124.03

Volume

173,885 shs

Average Volume

949,803 shs

Market Capitalization

$2.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Cowen Inc, Cowen Inc., Craig Hallum, Jefferies Financial Group Inc., Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, SVB Leerink LLC, TheStreet, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

14 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $75.50, suggesting a possible upside of 74.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting TNDM will reach $130.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $43.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

Other companies that are similar to Tandem Diabetes Care include NuVasive, Glaukos, Axonics, Inari Medical and iRhythm Technologies. Learn More about companies similar to Tandem Diabetes Care.

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com. Learn More about contacing Tandem Diabetes Care investor relations.